B. Metzler Seel. Sohn & Co. Ag Keros Therapeutics, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 16,103 shares of KROS stock, worth $254,910. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,103
Previous 16,103
-0.0%
Holding current value
$254,910
Previous $735,000
27.21%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding KROS
# of Institutions
174Shares Held
30.3MCall Options Held
76.8KPut Options Held
9K-
Black Rock Inc. New York, NY2.51MShares$39.8 Million0.0% of portfolio
-
Alkeon Capital Management LLC New York, NY1.9MShares$30 Million0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.86MShares$29.4 Million0.0% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.52MShares$24.1 Million7.2% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD1.51MShares$24 Million0.01% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $408M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...